Cite
Thiele K, Rau M, Hartmann NK, et al. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study. Diabetes Obes Metab. 2021;23(12):2814-2818doi: 10.1111/dom.14517.
Thiele, K., Rau, M., Hartmann, N. K., Möllmann, J., Jankowski, J., Böhm, M., Keszei, A. P., Marx, N., & Lehrke, M. (2021). Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study. Diabetes, obesity & metabolism, 23(12), 2814-2818. https://doi.org/10.1111/dom.14517
Thiele, Kirsten, et al. "Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study." Diabetes, obesity & metabolism vol. 23,12 (2021): 2814-2818. doi: https://doi.org/10.1111/dom.14517
Thiele K, Rau M, Hartmann NK, Möllmann J, Jankowski J, Böhm M, Keszei AP, Marx N, Lehrke M. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study. Diabetes Obes Metab. 2021 Dec;23(12):2814-2818. doi: 10.1111/dom.14517. Epub 2021 Aug 25. PMID: 34378852.
Copy
Download .nbib
